Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers.

Abstract

Objective: There is limited pharmacokinetic data available for the combination artesunate + amodiaquine, which is used widely to treat uncomplicated malaria. This study examines the bioavailability and tolerability of a fixed (200 mg artesunate + 540 mg amodiaquine) and loose (200 mg+612 mg) combination with a 2×2 cross-over design in 24 healthy volunteers.

Methods: Parent compounds and metabolites [dihydroartemisinin (DHA) and desethylamodiaquine (DEAQ)] were measured by high-performance liquid chromatography– electrochemical detection, and the area under the curve (AUC)<sub>0-t</sub> and C<sub>max</sub> were compared by an analysis of variance (ANOVA) based on geometric least square means using the Schuirmann two one-sided test.

Results: The AUC<sub>0-t</sub> for total DHA and DEAQ were 1522 ± 633 and 30021 ± 14211 ng h/ml for the fixed products and 1688 ± 767 and 40261 ± 19824 ng h/ml (mean ± standard deviation) for the loose products. The ANOVA showed no statistical differences except for sequence effect for DHA. The values obtained with the fixed product were within the 125% bioequivalent limits but extended below the 80% bioequivalence limits.

Conclusion: Both combinations were well tolerated and had comparable pharmacokinetic profiles; differences are unlikely to be clinically relevant.

Citation

European Journal of Clinical Pharmacology (2009) 65 (8), 809–821 [DOI:10.1007/s00228-009-0656-1].

Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers.

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.